Associated Papers
When the same treatment has different response: The role of pharmacogenomics in statin therapy.
Zheng E et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2024
SLCO1B1: Application and Limitations of Deep Mutational Scanning for Genomic Missense Variant Function.
Zhang L et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2021
Statin-induced myopathy SLCO1B1 521T > C is associated with prediabetes, high body mass index and normal lipid profile in Emirati population.
Saber-Ayad M et al.
Diabetes Research and Clinical Practice, 2018
Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition.
Zhou F et al.
Advanced Drug Delivery Reviews, 2017
Frequencies of single-nucleotide polymorphisms and haplotypes of the SLCO1B1 gene in selected populations of the western balkans.
Grapci AD et al.
Balkan Journal of Medical Genetics : Bjmg, 2015
Single nucleotide polymorphism markers for low-dose aspirin-associated peptic ulcer and ulcer bleeding.
Shiotani A et al.
Journal of Gastroenterology and Hepatology, 2014
Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study.
Donnelly LA et al.
Clinical Pharmacology and Therapeutics, 2011
SLCO1B1 polymorphism and oral antidiabetic drugs.
Kalliokoski A et al.
Basic & Clinical Pharmacology & Toxicology, 2010
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.
Romaine SP et al.
The Pharmacogenomics Journal, 2010
Select a paper to view details